Celgene (CELG) Given a $112.00 Price Target by Cantor Fitzgerald Analysts

Cantor Fitzgerald set a $112.00 price objective on Celgene (NASDAQ:CELG) in a research note issued to investors on Friday, December 29th. The firm currently has a hold rating on the biopharmaceutical company’s stock.

“CELG will record a pretax charge of approximately $411 million in 4Q17 in relation to the wind-down of the GED-0301 program, announced in October 2017.”,” the firm’s analyst wrote.

Several other research analysts have also recently commented on CELG. Oppenheimer set a $166.00 target price on Celgene and gave the stock a buy rating in a research note on Thursday, December 28th. Credit Suisse Group set a $123.00 price target on Celgene and gave the stock a buy rating in a report on Thursday, December 28th. Mizuho set a $128.00 price target on Celgene and gave the stock a buy rating in a report on Tuesday, December 26th. Sanford C. Bernstein downgraded Celgene from an outperform rating to a market perform rating and set a $121.00 price target for the company. in a report on Wednesday, December 27th. Finally, Guggenheim set a $152.00 price target on Celgene and gave the stock a buy rating in a report on Monday, December 25th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and nineteen have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus target price of $131.18.

Celgene (CELG) opened at $106.00 on Friday. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market capitalization of $83,460.00, a P/E ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the previous year, the firm posted $1.58 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. analysts forecast that Celgene will post 6.69 EPS for the current year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. KCS Wealth Advisory acquired a new stake in shares of Celgene in the 4th quarter worth approximately $562,000. Addenda Capital Inc. lifted its stake in Celgene by 4.8% in the 4th quarter. Addenda Capital Inc. now owns 57,843 shares of the biopharmaceutical company’s stock valued at $6,036,000 after buying an additional 2,626 shares in the last quarter. Hikari Power Ltd lifted its stake in Celgene by 25.4% in the 4th quarter. Hikari Power Ltd now owns 71,970 shares of the biopharmaceutical company’s stock valued at $7,511,000 after buying an additional 14,570 shares in the last quarter. Daiwa SB Investments Ltd. lifted its stake in Celgene by 15.9% in the 4th quarter. Daiwa SB Investments Ltd. now owns 10,040 shares of the biopharmaceutical company’s stock valued at $1,048,000 after buying an additional 1,380 shares in the last quarter. Finally, Lederer & Associates Investment Counsel CA lifted its stake in Celgene by 22.4% in the 4th quarter. Lederer & Associates Investment Counsel CA now owns 17,745 shares of the biopharmaceutical company’s stock valued at $1,852,000 after buying an additional 3,246 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/01/14/celgene-celg-given-a-112-00-price-target-at-cantor-fitzgerald-updated-updated.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply